BRIEF published on 04/15/2025 at 09:02, 1 year 4 months ago Carl Zeiss Meditec Reports Strong Q2 Earnings for 2024/25 Revenue Growth Refractive Surgery China Market Q2 2024/25 Earnings EBITA Increase
BRIEF published on 04/15/2025 at 09:02, 1 year 4 months ago Carl Zeiss Meditec annonce de solides résultats au deuxième trimestre 2024/25 Croissance Des Revenus Marché Chinois Chirurgie Réfractive Résultats Du Deuxième Trimestre 2024/25 Augmentation De L'EBITA
BRIEF published on 04/15/2025 at 08:37, 1 year 4 months ago Analysis of Salary Distribution in Germany by The Stepstone Group Germany Salary Distribution Top Earners Germany Regional Salary Differences Specialized Professionals Income Stepstone Salary Report 2025
BRIEF published on 04/15/2025 at 08:37, 1 year 4 months ago Analyse de la répartition des salaires en Allemagne par le groupe Stepstone Répartition Des Salaires En Allemagne Les Plus Hauts Revenus En Allemagne Différences Salariales Régionales Revenus Des Professionnels Spécialisés Rapport Sur Les Salaires Stepstone 2025
BRIEF published on 04/15/2025 at 08:35, 1 year 4 months ago Molten Ventures Executes Share Repurchase London Stock Exchange Share Repurchase Market Abuse Regulation Molten Ventures Deutsche Numis
BRIEF published on 04/15/2025 at 08:35, 1 year 4 months ago Molten Ventures procède au rachat d'actions Rachat D'actions Bourse De Londres Réglementation Sur Les Abus De Marché Deutsche Numis Entreprises En Fusion
BRIEF published on 04/15/2025 at 08:35, 1 year 4 months ago Rachat d'actions propres par Cie du Bois Sauvage Rachat D'actions Cie Du Bois Sauvage NYSE Euronext Bruxelles Transactions Boursières Assemblées Générales
BRIEF published on 04/15/2025 at 08:35, 1 year 4 months ago Compagnie du Bois Sauvage: Share Buyback Activity Overview Share Buyback Bois Sauvage Financial Disclosure Trading Activity Brussels Market
BRIEF published on 04/15/2025 at 08:22, 1 year 4 months ago Pentixapharm Holding AG Reports 2024 Financial Results and 2025 Outlook Research And Development Financial Results 2024 2025 Financial Forecast Radiopharmaceutical Innovation Pentixapharm Strategy
BRIEF published on 04/15/2025 at 08:22, 1 year 4 months ago Pentixapharm Holding AG publie ses résultats financiers pour 2024 et ses perspectives pour 2025 Recherche Et Développement Résultats Financiers 2024 Prévisions Financières 2025 Innovation Radiopharmaceutique Stratégie Pentixapharm
Published on 09/11/2026 at 23:00, 41 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 1 hour 36 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 2 hours 16 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 6 hours 41 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/11/2026 at 17:00, 6 hours 41 minutes ago Critical Elements sélectionné pour inclusion dans le prospectus du sommet Canadien de l'investissement, mettant le projet en valeur auprès d'investisseurs mondiaux de premier plan
Published on 09/11/2026 at 22:15, 1 hour 26 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 1 hour 31 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 3 hours 57 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 5 hours 26 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 16 hours 41 minutes ago Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 16 hours 41 minutes ago Transparency notification by Baltisse Group
Published on 09/11/2026 at 07:00, 16 hours 41 minutes ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 16 hours 41 minutes ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 4 hours ago Availability of the 2026 Interim Financial Report
